Federal Investment Fuels Versiti Blood Research Institute Growth
Bipartisan initiatives have taken a significant step towards fostering life-saving research for patients across the country. Recently enacted federal legislation has allocated $3 million specifically for the expansion of the Versiti Blood Research Institute (VBRI) in Wauwatosa, Wisconsin.
Strategic Funding for Groundbreaking Research
This federal funding is pivotal as it will contribute to the construction of a new facility addition dedicated to advancing critical research across various domains, including cancer, bleeding disorders, clotting conditions, and cellular therapies. Notably, this federal commitment supplements a previous state investment of $10 million, which was approved to enhance research capabilities and patient care.
Comments from Leadership on Research Impact
Chris Miskel, the president and CEO of Versiti, emphasized the importance of this financial backing, stating, "This investment honors the partnership between science and community. The Versiti Blood Research Institute expands hope for families throughout the United States facing blood cancers, hemophilia, sickle cell disease, and countless other conditions. We're grateful for the broad bipartisan support that recognizes blood health research as vital to Wisconsin and the nation."
Leading the Charge in Blood Health Research
Versiti Blood Research Institute is globally recognized as one of the foremost centers for blood health research. It brings together esteemed scientists, innovative biotechnology collaborators, and robust federal research funding to drive scientific discoveries. VBRI has been at the forefront of developing therapeutic solutions that save lives—ranging from advancements in hemorrhage control for military personnel to pioneering personalized cancer treatments and gene therapies aimed at changing lives for patients with hemophilia A.
Expansion Plans and Research Capacity Boost
The upcoming expansion, measuring an impressive 79,000 square feet, is set to feature state-of-the-art laboratories engineered to propel research forward. It will significantly increase VBRI's research capacity, nearly doubling it and dramatically hastening the transition of promising discoveries into next-generation treatments for blood-related disorders. The completion of the expansion is targeted for late 2026, promising to unlock new avenues for research and innovation.
Versiti's Impact and Workforce
Headquartered in Milwaukee, Versiti currently employs over 2,700 professionals distributed across various states, including Illinois, Indiana, Michigan, Ohio, Texas, and Wisconsin. This expansive workforce is dedicated to advancing blood health research and innovation, ultimately improving patient outcomes across the nation.
About Versiti
Versiti is a renowned leader in blood health innovation, committed to enhancing patient health outcomes while supporting its healthcare partners nationwide. The organization offers dynamic, high-value solutions in transfusion medicine, transplantation, and blood disease treatment, tailored to meet diverse customer needs. Collectively, the initiatives across Versiti lead to improved access to care, enhanced patient outcomes, and cost efficiencies for healthcare systems throughout the U.S.
Frequently Asked Questions
What is the purpose of the $3 million federal funding?
The funding is designed to support the expansion of the Versiti Blood Research Institute, enhancing its research capabilities for blood-related diseases.
How will the expansion impact research at Versiti?
The expansion will nearly double the research capacity of VBRI, enabling more advanced research into blood diseases and therapies.
What types of conditions is VBRI focusing on?
VBRI specializes in research areas such as cancer, hemophilia, sickle cell disease, and bleeding disorders.
Who leads Versiti Blood Research Institute?
Versiti is led by Chris Miskel, who serves as the president and CEO.
Where is Versiti headquartered?
Versiti is headquartered in Milwaukee, Wisconsin, with locations across several states, including Illinois, Indiana, and Michigan.
